AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02686138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01953978
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Trial: NCT01406444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
Trial: NCT01180426
Drug: CHR-2797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg once daily oral for 48 weeks
Trial: NCT00673049
Drug: CP 751,871 (Figitumumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
Trial: NCT00376038
Drug: GSK189075 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03616717
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
Trial: NCT00967655
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03510598
Drug: Kybella 20 MG in 2 ML Injection
RxNorm normalized name: Kybella 20 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable drug called KYBELLA® (deoxycholic acid)
Trial: NCT05300828
Drug: Genexl PM
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
Trial: NCT00201409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by slow intravenous infusion once daily for 14 days.
Trial: NCT00506792
Drug: QAU145
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00506792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04229927
Drug: BPDO-1603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Trial: NCT02045589
Drug: Abraxane®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m2 intravenous administration
Trial: NCT01855828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Trial: NCT01866098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01178710
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Trial: NCT01374269
Drug: NSAID (Nonsteroidal anti-inflammatory drugs)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
Trial: NCT00497913
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02813265
Drug: KPI-121 0.25% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02813265
Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00478244
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -5 through Day -2: 50 mg/kg IV over 120 min.
Trial: NCT00948324
Drug: CSII,ALA,MET,RSG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
Trial: NCT03669185
Drug: Pentalong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentalong, 2 x daily 1 tablet, intake max. 133 days
Trial: NCT03669185
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos, 2 x daily 1 tablet, intake max. 133 days
Trial: NCT03456388
Drug: placebo enteric-coated tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
Trial: NCT00663026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection once per week for 6 months
Trial: NCT01056289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Trial: NCT02487303
Drug: Acetaminophen Intravenous
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 1 gram f3 doses over 24 hours
Trial: NCT00358410
Drug: GW679769 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x GW679769 60mg tablets
Trial: NCT00358410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets to match experimental intervention
Trial: NCT01775189
Drug: ALO-02 weight-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed sugar spheres (powder) x 1 dose
Trial: NCT01775189
Drug: crushed ALO-02 30 mg/3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
Trial: NCT02974712
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03988686
Drug: Standard of care for metastatic prostate cancer
RxNorm normalized name: PROSTATE CONCENTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
Trial: NCT01755767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT04623086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
Trial: NCT01273896
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
Trial: NCT04380090
Drug: Propylene Glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
Trial: NCT02548390
Drug: RXDX-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
Trial: NCT00425373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablet and 2 capsule placebos taken once daily
Trial: NCT02597127
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (sterile, normal, 0.9%) solution given as SC injections
Trial: NCT01008462
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01365312
Drug: Ethanol lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
Trial: NCT01365312
Drug: Heparinized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
Trial: NCT03997279
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
Trial: NCT03997279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
Trial: NCT03526159
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
Trial: NCT00645632
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00645632
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01968187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days.
Trial: NCT00819637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
Trial: NCT01316315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as active
Trial: NCT00002737
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01680107
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000620
Drug: Anti-hyperglycemic Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
Trial: NCT00000620
Drug: Anti-hypertensive Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
Trial: NCT00000620
Drug: Blinded fenofibrate or placebo plus simvastatin
RxNorm normalized name: fenofibrate / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
Trial: NCT03238612
Drug: FFA, clarithromycin, oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
Trial: NCT02876757
Drug: 5ARI
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to finasteride/dutasteride
Trial: NCT01090518
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
Trial: NCT01006018
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
Trial: NCT03983915
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Trial: NCT03106987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Trial: NCT01739699
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01739699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134004
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00890604
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
Trial: NCT00925639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch pill
Trial: NCT00014352
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02871492
Drug: Zovirax® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01114607
Drug: GSK1605786 ChemoCentryx: formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
Trial: NCT01114607
Drug: GSK1605786 GSK: formulation B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Trial: NCT01114607
Drug: GSK1605786 GSK direct-fill: formulation C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
Trial: NCT01114607
Drug: GSK1605786 GSK modified-process: formulation D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Trial: NCT01114607
Drug: GSK1605786 GSK tablet: formulation E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
Trial: NCT01535092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
Trial: NCT02004015
Drug: injection of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg milligram(s)/kilogram
Trial: NCT02004015
Drug: injection of NMBA
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02558439
Drug: CNTX-4975
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03389815
Drug: WX-0593 Tablets
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
Trial: NCT02285088
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBT440 will be administered as oral capsules
Trial: NCT02285088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as oral capsules
Trial: NCT02676765
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
Trial: NCT00686361
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
Trial: NCT04274257
Drug: Double-Blind Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered.
Trial: NCT01207089
Drug: AZD8329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8329 Oral Solution 20mg/ml
Trial: NCT01207089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo AZD8329 Oral Solution
Trial: NCT03522831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
Trial: NCT04800679
Drug: PRP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
Trial: NCT00104494
Drug: Zinc acetate (20mg/d)
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
Trial: NCT00913718
Drug: Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913718
Drug: Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00536042
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: addition of 150 mg to 250 mg po bid to standard asthma care regiment
Trial: NCT04105205
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min infusion
Trial: NCT02108184
Drug: Sequential therapy 10 days
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
Trial: NCT02108184
Drug: Sequential therapy 14 days
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2